The impact of proprotein convertase subtilisin-kexin type 9 serine protease inhibitors on lipid levels and outcomes in patients with primary hypercholesterolaemia: a network meta-analysis (Q38636461)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	The impact of proprotein convertase subtilisin-kexin type 9 serine protease inhibitors on lipid levels and outcomes in patients with primary hypercholesterolaemia: a network meta-analysis	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

5 September 2017

0 references

The impact of proprotein convertase subtilisin-kexin type 9 serine protease inhibitors on lipid levels and outcomes in patients with primary hypercholesterolaemia: a network meta-analysis (English)

1 reference

Europe PubMed Central

PubMed publication ID

5 September 2017

hypercholesterolemia

0 references

1 reference

based on heuristic

inferred from title

Umberto Benedetto

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26578202%20AND%20SRC:MED&resulttype=core&format=json

7 June 2020

Giuseppe Biondi-Zoccai

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26578202%20AND%20SRC:MED&resulttype=core&format=json

7 June 2020

Thibault Lhermusier

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26578202%20AND%20SRC:MED&resulttype=core&format=json

7 June 2020

9

object named as

Ron Waksman

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26578202%20AND%20SRC:MED&resulttype=core&format=json

7 June 2020

Rebecca Torguson

7

object named as

Rebecca Torguson

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26578202%20AND%20SRC:MED&resulttype=core&format=json

7 June 2020

Ricardo O Escarcega

3

object named as

Ricardo O Escarcega

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26578202%20AND%20SRC:MED&resulttype=core&format=json

7 June 2020

Michael J Lipinski

1

object named as

Michael J Lipinski

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26578202%20AND%20SRC:MED&resulttype=core&format=json

7 June 2020

author name string

Nevin C Baker

6

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26578202%20AND%20SRC:MED&resulttype=core&format=json

7 June 2020

H Bryan Brewer

8

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26578202%20AND%20SRC:MED&resulttype=core&format=json

7 June 2020

language of work or name

1 reference

based on heuristic

inferred from title

publication date

17 November 2015

1 reference

Europe PubMed Central

PubMed publication ID

5 September 2017

European Heart Journal

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26578202%20AND%20SRC:MED&resulttype=core&format=json

7 June 2020

37

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26578202%20AND%20SRC:MED&resulttype=core&format=json

7 June 2020

6

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26578202%20AND%20SRC:MED&resulttype=core&format=json

7 June 2020

536-545

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26578202%20AND%20SRC:MED&resulttype=core&format=json

7 June 2020

Genetic risk, coronary heart disease events, and the clinical benefit of statin therapy: an analysis of primary and secondary prevention trials

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHV563

21 January 2018

Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHV563

21 January 2018

Effects of torcetrapib in patients at high risk for coronary events

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHV563

21 January 2018

Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHV563

21 January 2018

Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHV563

21 January 2018

Sequence variations in PCSK9, low LDL, and protection against coronary heart disease

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHV563

21 January 2018

A spectrum of PCSK9 alleles contributes to plasma levels of low-density lipoprotein cholesterol.

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHV563

21 January 2018

GRADE: an emerging consensus on rating quality of evidence and strength of recommendations

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHV563

21 January 2018

A graphical tool for locating inconsistency in network meta-analyses.

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHV563

21 January 2018

Markov chain Monte Carlo methods in biostatistics.

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHV563

21 January 2018

Comparison of two methods to detect publication bias in meta-analysis

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHV563

21 January 2018

Efficacy and safety of longer-term administration of evolocumab (AMG 145) in patients with hypercholesterolemia: 52-week results from the Open-Label Study of Long-Term Evaluation Against LDL-C (OSLER) randomized trial

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHV563

21 January 2018

AMG145, a monoclonal antibody against proprotein convertase subtilisin kexin type 9, significantly reduces lipoprotein(a) in hypercholesterolemic patients receiving statin therapy: an analysis from the LDL-C Assessment with Proprotein Convertase Sub

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHV563

21 January 2018

ODYSSEY MONO: effect of alirocumab 75 mg subcutaneously every 2 weeks as monotherapy versus ezetimibe over 24 weeks

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHV563

21 January 2018

Effect of alirocumab, a monoclonal proprotein convertase subtilisin/kexin 9 antibody, on lipoprotein(a) concentrations (a pooled analysis of 150 mg every two weeks dosing from phase 2 trials).

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHV563

21 January 2018

Reduction in lipoprotein(a) with PCSK9 monoclonal antibody evolocumab (AMG 145): a pooled analysis of more than 1,300 patients in 4 phase II trials.

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHV563

21 January 2018

Effect of the proprotein convertase subtilisin/kexin 9 monoclonal antibody, AMG 145, in homozygous familial hypercholesterolemia

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHV563

21 January 2018

Effects of AMG 145 on low-density lipoprotein cholesterol levels: results from 2 randomized, double-blind, placebo-controlled, ascending-dose phase 1 studies in healthy volunteers and hypercholesterolemic subjects on statins

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHV563

21 January 2018

Effect of a monoclonal antibody to PCSK9 on LDL cholesterol

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHV563

21 January 2018

Modeling and Simulation to Support Phase 2 Dose Selection for RG7652, a Fully Human Monoclonal Antibody Against Proprotein Convertase Subtilisin/Kexin Type 9.

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHV563

21 January 2018

Effect of alirocumab, a monoclonal antibody to PCSK9, on long-term cardiovascular outcomes following acute coronary syndromes: rationale and design of the ODYSSEY outcomes trial

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHV563

21 January 2018

Efficacy and safety of alirocumab, a monoclonal antibody to PCSK9, in statin-intolerant patients: design and rationale of ODYSSEY ALTERNATIVE, a randomized phase 3 trial

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHV563

21 January 2018

A 52-week placebo-controlled trial of evolocumab in hyperlipidemia

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHV563

21 January 2018

Effect of a monoclonal antibody to PCSK9 on low-density lipoprotein cholesterol levels in statin-intolerant patients: the GAUSS randomized trial.

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHV563

21 January 2018

Anti-PCSK9 antibody effectively lowers cholesterol in patients with statin intolerance: the GAUSS-2 randomized, placebo-controlled phase 3 clinical trial of evolocumab.

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHV563

21 January 2018

Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 in combination with a statin in patients with hypercholesterolaemia (LAPLACE-TIMI 57): a randomised, placebo-controlled, dose-ranging, phase

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHV563

21 January 2018

Effect of evolocumab or ezetimibe added to moderate- or high-intensity statin therapy on LDL-C lowering in patients with hypercholesterolemia: the LAPLACE-2 randomized clinical trial.

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHV563

21 January 2018

Safety and efficacy of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease, SAR236553/REGN727, in patients with primary hypercholesterolemia receiving ongoing stable atorvastatin therapy

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHV563

21 January 2018

Anti-PCSK9 monotherapy for hypercholesterolemia: the MENDEL-2 randomized, controlled phase III clinical trial of evolocumab

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHV563

21 January 2018

Efficacy and safety of alirocumab in high cardiovascular risk patients with inadequately controlled hypercholesterolaemia on maximally tolerated doses of statins: the ODYSSEY COMBO II randomized controlled trial

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHV563

21 January 2018

Efficacy and safety of alirocumab in reducing lipids and cardiovascular events

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHV563

21 January 2018

Efficacy and safety of evolocumab in reducing lipids and cardiovascular events.

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHV563

21 January 2018

Low-density lipoprotein cholesterol-lowering effects of AMG 145, a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease in patients with heterozygous familial hypercholesterolemia: the Reduction of LDL-C with PCSK9 In

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHV563

21 January 2018

PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHV563

21 January 2018

Effect of a monoclonal antibody to PCSK9, REGN727/SAR236553, to reduce low-density lipoprotein cholesterol in patients with heterozygous familial hypercholesterolaemia on stable statin dose with or without ezetimibe therapy: a phase 2 randomised con

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHV563

21 January 2018

Effects of evolocumab (AMG 145), a monoclonal antibody to PCSK9, in hypercholesterolemic, statin-treated Japanese patients at high cardiovascular risk--primary results from the phase 2 YUKAWA study

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHV563

21 January 2018

Effects of Proprotein Convertase Subtilisin/Kexin Type 9 Antibodies in Adults With Hypercholesterolemia: A Systematic Review and Meta-analysis

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHV563

21 January 2018

Mutations in PCSK9 cause autosomal dominant hypercholesterolemia

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHV563

21 January 2018

Secreted PCSK9 decreases the number of LDL receptors in hepatocytes and in livers of parabiotic mice

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHV563

21 January 2018

Efficacy and safety of the proprotein convertase subtilisin/kexin type 9 inhibitor alirocumab among high cardiovascular risk patients on maximally tolerated statin therapy: The ODYSSEY COMBO I study

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHV563

21 January 2018

Monotherapy with the PCSK9 inhibitor alirocumab versus ezetimibe in patients with hypercholesterolemia: Results of a 24week, double-blind, randomized Phase 3 trial

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHV563

21 January 2018

Identifiers

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q38636461&oldid=1771658143"